CivicaScript Launches Generic Abiraterone
Abiraterone is used together with prednisone to treat patients with metastatic prostate cancer.
CivicaScript is now offering to pharmacies abiraterone 250 mg for $160 per bottle of 120 tablets, which is typically a month’s supply . CivicaScript recommends that pharmacies charge patients no more than $171 per bottle (CivicaScript’s maximum retail price).
This is significantly less than prices offered at many pharmacies, according to GoodRx. The lowest GoodRx price for the most common version of abiraterone is around $187.00, 96% off the average retail price of $5,024.47.
Abiraterone is hormone therapy that is used together with prednisone to treat patients with metastatic prostate cancer. Its branded counterparts include Janssen’s Zytiga, which is available as 250 mg or 500 mg tablets, and Sun Pharma’s Yonsa, which is available as a 125 mg tablet.
Initially, CivicaScript’s abiraterone will be available through Lumicera Health Services, a specialty pharmacy that focuses on medicines for chronic and serious conditions, and through Intermountain Healthcare. Additional pharmacies will be listed on the CivicaScript website as they come on board.
Starting in 2024, CivicaScript plans to distribute low-priced insulin. Civica is building a manufacturing facility in Petersburg, Virginia, and has entered into a co-development and commercial agreement with GeneSys Biologics for three insulin biosimilars: glargine, lispro and aspart (biologics corresponding to Lantus, Humalog and Novolog, respectively).Civica plans to set a recommended price to the consumer of no more than $30 per insulin vial and no more than $55 for a box of five insulin pen cartridges, a significant discount to prices charged to uninsured individuals today.
Related: Civica’s Allan Coukell Talks about Its Insulin Program
Kim A. Keck
CivicaScript was co-founded in 2020 by Civica Inc., the Blue Cross Blue Shield Association (BCBSA) and 18 independent and locally operated Blue Cross and Blue Shield (BCBS) companies to bring affordable versions of common but high-priced generic medicines to market.
Additionally, the pharmacy benefit manager Navitus Health Solutions last month announced it had joined CivicaScript as a founding member, offering CivicaScript’s products alongside other therapies, and members will be incentivized to use those.
“This is an important milestone in our shared commitment to help make prescription drugs more affordable for millions of Americans. No one should have to face breaking the bank from buying a life-saving medication,” Kim Keck, president and CEO of BCBSA, said in a statement.
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
FDA Approves Tevimbra for Advanced Esophageal Cancer at $15,828 Per Month
March 5th 2025Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that by 2040, there will be approximately 957,000 new cases of esophageal cancer worldwide, marking a nearly 60% increase from 2020, according to BeiGene.
Read More
